en · de · es · fr · pt
cardarine-notes.peptides4800.com › Faq › Identity And Pharmacological Mechanism — Reference Sheet

Identity And Pharmacological Mechanism — Reference Sheet

By Editorial Desk · published 2026-04-22 · last reviewed 2026-05-07 · Faq

This is a working overview of Anti-doping testing, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-05-07. Anything still debated is marked as such rather than presented as settled.

Identity and Pharmacological Mechanism

Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Background and Regulatory Status

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Cardarine at a glance

PropertyValueNotes
Chemical classSynthetic PPARδ agonistNot a steroid or a selective androgen receptor modulator.
Common synonymsCardarine, GW501516, GW-501516, endurobolNames vary by supplier and literature source.
AppearanceWhite to off-white powderConsistent with many small-molecule research chemicals.
SolubilityLow in water; soluble in DMSO and ethanolOften prepared in organic solvent for laboratory work.
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid and energy metabolism.

Regulatory Status and Detection Context

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Related pages on this site

Background and Regulatory History

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

Reference notes

Cohn (1993), assistant secretary for strategy, planning, analysis & risk of the United States Department of Homeland Security Amit Bose (1994), acting administrator of the Federal Railroad Administration Karthik Ramanathan (1994), acting assistant secretary of the treasury for financial markets Frank Scaturro (1994), lawyer, public advocate who spearheaded the restoration of Grant's Tomb; Republican candidate for New York's 4th congressional district Radhika Fox (1995), acting assistant administrator for water of the United States Environmental Protection Agency Beto O'Rourke (1995), U.S. congressman for Texas's 16th congressional district and candidate in the 2020 United States presidential election Rebekah Gee (1997), secretary of the Louisiana Department of Health, daughter of Ohio State University president E. Gordon Gee Jay Carson (1999), executive director of C40 Cities Climate Leadership Group; former press secretary for Hillary Clinton and Howard Dean's presidential campaigns John Ray Clemmons (1999), member of the Tennessee House of Representatives from the 55th district George Demos (1999), former U.S.

The Orange Book, formally titled Compendium of Analytical Nomenclature, contains internationally accepted definitions for terms in analytical chemistry. It has traditionally been published in an orange cover. Although the book is described as the "Definitive Rules", there have been three editions published; the first in 1978 (ISBN 0-08022-008-8), the second in 1987 (ISBN 0-63201-907-7) and the third in 1998 (ISBN 0-86542-615-5). The third edition is also available online. A Catalan translation has also been published (1987, ISBN 84-7283-121-3).

TCFH can also be used in other reactions involving activation of carboxylic acids from reactions with oxygen-, sulfur- and carbon-nucleophiles for the preparation of esters, thioesters and ketones. Extending beyond reactions with carboxylic acids, TCFH has been shown to be an activator for other oxygen centered nucleophiles, including heterocyclic alcohols, ketooximes, and even alcohols. Reactivity with sulfur centered nucleophiles like thioureas has also been demonstrated.

== Research == A 2003 systematic review found that kava extract reduced anxiety symptoms compared to placebo, with a small effect size and mostly mild, transient side effects. Kava may help with anxiety after several weeks of use. Meta-analyses suggest kava can reduce anxiety symptoms – sometimes comparably to medications like oxazepam and buspirone – with strongest evidence seen in multiweek studies using aqueous extracts for generalized anxiety disorder, although results were mixed and standardized trials are limited. Current evidence does not support its effectiveness for generalized anxiety disorder or other conditions. Kava has no proven effects on cancer, cognitive function, or microbial infections. Kava generally does not impair cognition at therapeutic doses and may enhance attention and memory at lower doses, but may reduce visual attention at higher or recreational doses; heterogeneity in study design, dosage, preparation, and small sample sizes limits definitive conclusions. A study of heavy and long-term kava users in northern Australia found no evidence of cognitive or brain dysfunction despite some physical health effects, including liver enzyme elevation and skin changes.

Born: Kim Jong Un, Supreme Leader of North Korea since the 2011 death of his father, Kim Jong Il, and General Secretary of the Workers' Party of Korea since 2012; in Pyongyang Khaled bin Mohamed Al Nahyan, Crown Prince of Abu Dhabi, son of Mohamed bin Zayed Al Nahyan and grandson of Zayed bin Sultan Al Nahyan, President of the United Arab Emirates; in Abu Dhabi Died: Reta Shaw, 69, American character actress in film and television, known for Mary Poppins Sidney Robinson Jr., 79, American physiologist and former Olympic athlete known for his research into developing uniforms to minimize thermal stress on the human body Lucille Lee Stewart, 92, American silent film actress

Sources: en.wikipedia.org

Notes from published material

==== Training with copyrighted content ==== Generative AI systems such as ChatGPT and Midjourney are trained on large, publicly available datasets that include copyrighted works. AI developers have argued that such training is protected under fair use, while copyright holders have argued that it infringes their rights. Proponents of fair use training have argued that it is a transformative use and does not involve making copies of copyrighted works available to the public. Critics have argued that image generators such as Midjourney can create nearly-identical copies of some copyrighted images, and that generative AI programs compete with the content they are trained on. As of 2024, several lawsuits related to the use of copyrighted material in training are ongoing. Getty Images has sued Stability AI over the use of its images to train Stable Diffusion. Both the Authors Guild and The New York Times have sued Microsoft and OpenAI over the use of their works to train ChatGPT.

After around 8 weeks customised foot orthoses can offer short-term relief. Other treatments have little supportive evidence and studies. These include rest, massage, heat, ice, and calf-strengthening exercises, weight reduction in the overweight or obese, and nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen. NSAID use is common, but fails to resolve pain in 20% of people. Corticosteroid injections are sometimes used for cases resistant to more conservative measures. Tentative evidence supports their use for short-term pain relief up to one month (only). Comparative evidence suggests that short- and long-term treatment effects vary. Corticosteroid injections may provide greater short-term pain relief, but their benefits then fade. In contrast, therapies such as platelet-rich plasma (PRP) and ESWT are associated with improved pain and functional outcomes over longer follow-up periods. However, studies remain inconsistent, and evidence quality is limited by variability in study design, treatment protocols, and outcome measures. As a result, no single treatment is established as universally superior. Another treatment technique is plantar iontophoresis. This technique involves applying anti-inflammatory substances such as dexamethasone or acetic acid topically to the foot and transmitting these substances through the skin with an electric current. Some evidence supports the use of night splints for 1–3 months to relieve pain after six months.

== Prognosis == As of March 2020, only 50 cases of CMRD have been documented in the medical literature. This small number speaks to the rarity of the disease as well as the lack of thorough research and documentation. As a result, the full course of the disease, life expectancy, and mortality are also poorly documented. Clinical manifestation of CMRD symptoms begin during infancy and early childhood but may go undetected due to the non-specific symptoms associated with the disease. Many of these symptoms can be attributed to malnutrition and nonspecific postnatal diarrhea, confounding early diagnosis. Careful regulation of diet and nutrition are required for management of CMRD since the disease results from the poor absorption of nutrients from food.

The three substrates of this enzyme are N5-(L-1-carboxyethyl)-L-ornithine, oxidised nicotinamide adenine dinucleotide phosphate (NADP+), and water. Its products are L-ornithine, reduced NADPH, pyruvic acid, and a proton.

The aorta is the root systemic artery (i.e., main artery). In humans, it receives blood directly from the left ventricle of the heart via the aortic valve. As the aorta branches and these arteries branch, in turn, they become successively smaller in diameter, down to the arterioles. The arterioles supply capillaries, which in turn empty into venules. The first branches off of the aorta are the coronary arteries, which supply blood to the heart muscle itself. These are followed by the branches of the aortic arch, namely the brachiocephalic artery, the left common carotid, and the left subclavian arteries.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.

How does cardarine interact with the body?

It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.

Is cardarine found naturally?

No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.

Is cardarine approved for human use?

No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.

Network